Breaking News Instant updates and real-time market news.

KMPH

KemPharm

$3.70

-0.15 (-3.90%)

07:32
11/29/16
11/29
07:32
11/29/16
07:32

KemPharm receives from FDA to initiate clinical program for KP201/IR

KemPharm announced that its Investigational New Drug, or IND, application for KP201/IR has been accepted by the FDA. KP201/IR, KemPharm's co-lead product candidate, is a single-entity benzhydrocodone HCl immediate release abuse-deterrent prodrug for the treatment of acute pain. KemPharm expects to conduct human clinical trials of KP201/IR in 2017.

  • 29

    Nov

KMPH KemPharm
$3.70

-0.15 (-3.90%)

02/10/16
COWN
02/10/16
NO CHANGE
COWN
KemPharm's KP201 NDA accepted, says Cowen
Cowen said KemPharm's KP201 NDA has been accepted by the FDA and believes it will likely be the first hydrocodone/APAP product with abuse-deterrent claims. If approved, the firm's analyst expects clinicians will likely prescribe KP201 over other significantly more abusable options, driving significant share value from these levels.
05/06/16
OPCO
05/06/16
NO CHANGE
Target $11
OPCO
Outperform
KemPharm price target lowered to $11 from $28 at Oppenheimer
Oppenheimer analyst Rohit Vanjani lowered his price target for KemPharm to $11 from $28 given the higher risk of a non-approval or approval without AD labeling for the company's Apadaz after a negative FDA Advisory Committee meeting. Though panel members voted that Apadaz should get approved based on the bioequivalence data to the reference drug, the members voted against labeling it as an abuse-deterrent product, the analyst tells investors in a research note. However, Vanjani believes this will not be the "end of the story," reiterating an Outperform rating on the shares while he awaits further commentary from the FDA.
05/06/16
RBCM
05/06/16
NO CHANGE
RBCM
KemPharm price target lowered to $14 from $22 at RBC Capital
RBC Capital cut its price target on KemPharm after an FDA panel voted 16-4 to recommend approval of the company's Apadaz drug but voted 18-2 against inclusion of an abuse deterrent claim in the label. The firm says that the abuse deterrent label was the key to the drug's success. Nonetheless, the firm remains upbeat on the company's technology, and it keeps an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

05:49
09/25/17
09/25
05:49
09/25/17
05:49
Hot Stocks
Amazon Web Services announces opening of data centers in Middle East by 2019 »

Amazon Web Services, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

CVE

Cenovus Energy

$10.28

0.18 (1.78%)

05:46
09/25/17
09/25
05:46
09/25/17
05:46
Hot Stocks
Cenovus Energy reaches agreement to sell Suffield assets for $512M »

Cenovus Energy has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JHG

Janus Henderson Group

$33.96

0.42 (1.25%)

05:39
09/25/17
09/25
05:39
09/25/17
05:39
Initiation
Janus Henderson Group initiated  »

Janus Henderson Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMES

Emerge Energy

$9.17

0.44 (5.04%)

05:36
09/25/17
09/25
05:36
09/25/17
05:36
Initiation
Emerge Energy initiated  »

Emerge Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCLP

Hi-Crush Partners

$10.10

0.3 (3.06%)

05:34
09/25/17
09/25
05:34
09/25/17
05:34
Initiation
Hi-Crush Partners initiated  »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

EXEL

Exelixis

$24.47

-3.54 (-12.64%)

, DSNKY

Daiichi Sankyo

$23.03

0.17 (0.74%)

05:34
09/25/17
09/25
05:34
09/25/17
05:34
Hot Stocks
Exelixis: ESAX-HTN pivotal study in essential hypertension met primary objective »

Exelixis (EXEL) announced…

EXEL

Exelixis

$24.47

-3.54 (-12.64%)

DSNKY

Daiichi Sankyo

$23.03

0.17 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

VFC

VF Corp.

$62.20

0.35 (0.57%)

, UAA

Under Armour

$16.41

-0.08 (-0.49%)

05:31
09/25/17
09/25
05:31
09/25/17
05:31
Downgrade
VF Corp., Under Armour, Under Armour rating change  »

VF Corp. downgraded to…

VFC

VF Corp.

$62.20

0.35 (0.57%)

UAA

Under Armour

$16.41

-0.08 (-0.49%)

UA

Under Armour

$15.04

-0.09 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

UAA

Under Armour

$16.41

-0.08 (-0.49%)

, UA

Under Armour

$15.04

-0.09 (-0.59%)

05:28
09/25/17
09/25
05:28
09/25/17
05:28
Upgrade
Under Armour, Under Armour, VF Corp. rating change  »

Under Armour upgraded to…

UAA

Under Armour

$16.41

-0.08 (-0.49%)

UA

Under Armour

$15.04

-0.09 (-0.59%)

VFC

VF Corp.

$62.20

0.35 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

SNAP

Snap

$13.70

-0.07 (-0.51%)

05:24
09/25/17
09/25
05:24
09/25/17
05:24
Recommendations
Snap analyst commentary  »

Snap price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMP

Compass Minerals

$60.10

-9.4 (-13.53%)

05:20
09/25/17
09/25
05:20
09/25/17
05:20
Upgrade
Compass Minerals rating change  »

Compass Minerals upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Sep

  • 29

    Sep

COR

CoreSite Realty

$108.49

-1.86 (-1.69%)

05:18
09/25/17
09/25
05:18
09/25/17
05:18
Initiation
CoreSite Realty initiated  »

CoreSite Realty initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

ROST

Ross Stores

$60.89

-0.02 (-0.03%)

05:17
09/25/17
09/25
05:17
09/25/17
05:17
Upgrade
Ross Stores rating change  »

Ross Stores upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OFC

Corporate Office Properties

$32.53

-0.13 (-0.40%)

05:11
09/25/17
09/25
05:11
09/25/17
05:11
Upgrade
Corporate Office Properties rating change  »

Corporate Office…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMRF

ABN Amro

05:08
09/25/17
09/25
05:08
09/25/17
05:08
Upgrade
ABN Amro rating change  »

ABN Amro upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$39.42

0.32 (0.82%)

05:05
09/25/17
09/25
05:05
09/25/17
05:05
Upgrade
General Motors rating change  »

General Motors upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGLOY

Anglo American

$9.12

-0.1 (-1.08%)

04:59
09/25/17
09/25
04:59
09/25/17
04:59
Downgrade
Anglo American rating change  »

Anglo American downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTB

Butterfield

$36.57

0.45 (1.25%)

04:56
09/25/17
09/25
04:56
09/25/17
04:56
Downgrade
Butterfield rating change  »

Butterfield downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSAR

Versartis

$2.68

-18.925 (-87.62%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Downgrade
Versartis rating change  »

Versartis downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
Cowen retail analyst hold an analyst/industry conference call »

Retailing/Specialty…

HSC

Harsco

$19.75

0.35 (1.80%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
Harsco management to meet with Lake Street »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

IIVI

II-VI

$40.40

0.45 (1.13%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
II-VI management to meet with B. Riley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 28

    Sep

  • 13

    Nov

AMCX

AMC Networks

$59.08

0.14 (0.24%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
AMC Networks management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

04:55
09/25/17
09/25
04:55
09/25/17
04:55
General news
Dallas Fed Mfg Survey General Activity Index to be reported at 10:30 »

September Dallas Fed Mfg…

04:55
09/25/17
09/25
04:55
09/25/17
04:55
General news
Chicago Fed National Activity Index Level to be reported at 08:30 »

August Chicago Fed…

HES

Hess Corp.

$44.50

0.87 (1.99%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
Hess Corp. management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.